Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
Pharmacoepidemiology and Drug Safety
|
September 16, 2020
Gastrointestinal bleeding risk with rivaroxaban vs aspirin in atrial fibrillation: A multinational study
Laura Fanning, Ian C K Wong, Xue Li, et al.
Plos One
|
August 27, 2024
Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry
Adam Irving, Dennis Petrie, Anthony Harris, et al.
The Medical Journal of Australia
|
August 16, 2023
Activating pharmacists to reduce the frequency of medication-related problems (ACTMed): a stepped wedge cluster randomised trial
Jean Spinks, Richard Violette, Douglas Ir Boyle, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
June 19, 2019
Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054
Miroslaw Brys, Laura Fanning, Serena Hung, et al.
Muscle & Nerve
|
February 28, 2025
Serious Neurologic Adverse Events in Tofersen Clinical Trials for Amyotrophic Lateral Sclerosis
Alexandra Lovett, Sowmya Chary, Suma Babu, et al.
Annals of Emergency Medicine
|
November 19, 2018
A Cost-Effectiveness Analysis Comparing Clinical Decision Rules PECARN, CATCH, and CHALICE With Usual Care for the Management of Pediatric Head Injury
Kim Dalziel, John A Cheek, Laura Fanning, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
September 29, 2022
Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
Michael Benatar, Joanne Wuu, Peter M Andersen, et al.
Blood Advances
|
March 14, 2024
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies
Sara Carrillo de Albornoz, Alisa M Higgins, Dennis Petrie, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
May 18, 2022
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
Michael Benatar, Joanne Wuu, Peter M Andersen, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
February 21, 2016
Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies
David Sloane, Usha Govindarajulu, Jacob Harrow-Mortelliti, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
Pharmacoepidemiology and Drug Safety
|
September 16, 2020
Gastrointestinal bleeding risk with rivaroxaban vs aspirin in atrial fibrillation: A multinational study
Laura Fanning, Ian C K Wong, Xue Li, et al.
Plos One
|
August 27, 2024
Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry
Adam Irving, Dennis Petrie, Anthony Harris, et al.
The Medical Journal of Australia
|
August 16, 2023
Activating pharmacists to reduce the frequency of medication-related problems (ACTMed): a stepped wedge cluster randomised trial
Jean Spinks, Richard Violette, Douglas Ir Boyle, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
June 19, 2019
Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054
Miroslaw Brys, Laura Fanning, Serena Hung, et al.
Muscle & Nerve
|
February 28, 2025
Serious Neurologic Adverse Events in Tofersen Clinical Trials for Amyotrophic Lateral Sclerosis
Alexandra Lovett, Sowmya Chary, Suma Babu, et al.
Annals of Emergency Medicine
|
November 19, 2018
A Cost-Effectiveness Analysis Comparing Clinical Decision Rules PECARN, CATCH, and CHALICE With Usual Care for the Management of Pediatric Head Injury
Kim Dalziel, John A Cheek, Laura Fanning, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
September 29, 2022
Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
Michael Benatar, Joanne Wuu, Peter M Andersen, et al.
Blood Advances
|
March 14, 2024
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies
Sara Carrillo de Albornoz, Alisa M Higgins, Dennis Petrie, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
May 18, 2022
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
Michael Benatar, Joanne Wuu, Peter M Andersen, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
February 21, 2016
Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies
David Sloane, Usha Govindarajulu, Jacob Harrow-Mortelliti, et al.
Page
of 4